Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies
Recruiting now · Phase 1
Conditions studied: Pediatric Hematologic Malignancies
In brief
This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a novel graft modification technique (selective αβ-TCR and CD19 depletion).
Key facts
- Study ID
- NCT05011422
- Run by
- Washington University School of Medicine
- People needed
- 50
- Starts
- 2022-11-03
- Expected to finish
- 2029-05-31
- Last updated by the study team
- 2026-03-16
Who can join
Age: any, up to 30. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.